| Product name | CMS121 |
| Other name | CMS-121; 1,2-Benzenediol,4-[4-(cyclopentyloxy)-2-quinolinyl]-; 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol(CMS121); ACC,AcetylCoenzymeACarboxylase,disease,neuroprotective,inhibit,anti-inflammatory,mitochondrial,Alzheimer's,antioxidative,acetylation,Inhibitor,H3K9,Acetyl-CoACarboxylase,CMS121,dementia,ACC1,CMS-121 |
| CAS No. | 1353224-53-9 |
| Molecular formula | C20H19NO3 |
| Molecular weight | 321.37 |
| Purity | 98.0% |
| Appearance | Solid |
| Application | Dietary Supplement Raw Material |
CMS-121 is a quinolone derivative and orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor with promising pharmacological properties. Extensive research has been conducted to investigate the potential benefits of CMS-121 in various areas, including neuroprotection, anti-inflammatory effects, antioxidative activity, and its impact on aging-related markers. This compound has shown great potential as a therapeutic agent for the treatment and prevention of neurological disorders, cognitive decline, and age-related conditions.Neuroprotection: In studies conducted on HT22 cells, CMS-121 has demonstrated significant neuroprotective effects. It effectively protects these cells against ischemia and oxidative damage, as evidenced by its low EC50 values of 7 nM and 200 nM, respectively. The ability of CMS-121 to safeguard neuronal cells suggests its potential in combating ischemic conditions and oxidative stress-induced neurological disorders. Anti-inflammatory and Antioxidative Effects: CMS-121 exhibits remarkable anti-inflammatory properties, indicating its ability to modulate the inflammatory response. By doing so, CMS-121 has the potential to alleviate inflammation in various tissues and organs, thus holding promise for the treatment of inflammatory diseases. Additionally, CMS-121 demonstrates potent antioxidative activity, allowing it to counteract oxidative stress-induced damage. This antioxidative property makes CMS-121 an intriguing candidate for addressing diseases characterized by oxidative stress. Impact on Aging-related Markers: Preliminary studies conducted on rapidly aging SAMP8 mice have shown promising results for CMS-121. Oral administration of CMS-121 over a period of 4 months resulted in reduced cognitive decline, improved metabolic markers, and mitigated transcriptional markers associated with aging in the brain. Furthermore, CMS-121 was found to preserve mitochondrial homeostasis by regulating acetyl-CoA metabolism. These findings suggest that CMS-121 may have potential therapeutic applications in combating age-related cognitive impairments and age-related molecular changes.
(4) Antioxidative activity: CMS-121 displays strong antioxidative activity, allowing it to counteract oxidative stress-induced damage. This antioxidative capacity holds potential for addressing diseases associated with oxidative stress. (5) Renoprotective activity: CMS-121 demonstrates renoprotective effects, suggesting its potential in the protection and preservation of renal function. Further research is warranted to elucidate the mechanisms underlying its renoprotective activity. (6) Regulation of acetyl-CoA metabolism: CMS-121 regulates acetyl-CoA metabolism, thereby preserving mitochondrial homeostasis. This regulation may contribute to its neuroprotective and anti-aging effects, as well as its potential therapeutic applications in age-related disorders. (7) Oral bioavailability: CMS-121 can be administered orally, allowing for convenient and efficient delivery. Its ability to be absorbed and distributed within the body facilitates its potential as an orally active therapeutic agent. (8) Potential in aging-related conditions: CMS-121 shows promise in mitigating cognitive decline, metabolic markers, and transcriptional markers associated with aging in the brain. These effects position CMS-121 as a potential intervention for age-related cognitive impairments and molecular changes.(1) Potent activity: CMS-121 exhibits strong pharmacological activity as an acetyl-CoA carboxylase 1 (ACC1) inhibitor. Its potent inhibitory effect on ACC1 makes it a promising compound for various therapeutic applications. (2) Neuroprotective effects: CMS-121 demonstrates significant neuroprotective properties, safeguarding HT22 cells against ischemic and oxidative damage. This neuroprotective activity suggests its potential in the treatment of neurological disorders characterized by such damage. (3)Anti-inflammatory activity: CMS-121 exhibits notable anti-inflammatory effects, indicating its ability to modulate the inflammatory response. This property opens up possibilities for the treatment of inflammatory diseases where regulation of inflammation is crucial.
